Cover Image
Market Research Report

Market Spotlight: Endometriosis

Published by Datamonitor Healthcare Product code 573556
Published Content info 36 Pages
Delivery time: 1-2 business days
Price
Back to Top
Market Spotlight: Endometriosis
Published: February 5, 2019 Content info: 36 Pages
Description

This Market Spotlight report covers the Endometriosis market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

  • Datamonitor Healthcare estimates that in 2017, there were 188.7 million prevalent cases of endometriosis in women aged 15-49 years worldwide, and forecasts that number to increase to 199.1 million prevalent cases by 2026. Endometriosis affects an estimated one in 10 women in the reproductive age group of 15-49 years. The approved drugs in the endometriosis space target the gonadotropin-releasing hormone receptor, progesterone receptor, follicle-stimulating hormone, and androgen receptors. The majority of marketed drugs are administered via the subcutaneous route, while oral and intramuscular formulations are also available.
  • The majority of industry-sponsored drugs in active clinical development for endometriosis are in Phase II, with one drug each in Phase I and Phase III.
  • Therapies in mid-to-late-stage development for endometriosis focus on targets such as the gonadotropin-releasing hormone receptor, progesterone receptor, luteinizing hormone receptor, androgen receptors, and follicle-stimulating hormone. The majority of pipeline drugs in mid-to-late-stage development for endometriosis are administered via the oral route, with only one product being tested as a topical formulation.
  • High-impact upcoming events in the endometriosis space comprise topline Phase III trial results for Relugolix. The overall likelihood of approval of a Phase I gynecology asset is 13.1%, and the average probability a drug advances from Phase III is 62.5%. Drugs, on average, take 11.1 years from Phase I to approval, compared to 12.0 years in the overall obstetrics/gynecology space.
  • There have been 12 licensing and asset acquisition deals involving endometriosis drugs during 2014-19. The largest deal was in 2017, when AstraZeneca obtained commercialization rights to Zoladex in the US and Canada from TerSera Therapeutics for $320m.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for endometriosis have been in the early and mid-phases of development, with 75% of trials in Phase I-II, and only 25% in Phase III-IV.
  • The US has a substantial lead in the number of endometriosis clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the endometriosis space is dominated by completed trials. Bayer has the highest number of completed clinical trials for endometriosis, with 34 trials.
  • Bayer leads industry sponsors with the highest number of clinical trials for endometriosis, followed by Takeda.
Table of Contents
Product Code: DMKC0178894

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • GnRH analogs
  • Progestins
  • Combined oral contraceptives
  • Non-steroidal anti-inflammatory drugs
  • Danocrine
  • Surgery

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • OBE2109 for Endometriosis (June 18, 2018)
  • Proellex (Oral) for Endometriosis (July 17, 2017)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • AbbVie And Neurocrine Biosciences' Elagolix For Endometriosis

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of endometriosis, 2017-26
  • Figure 2: Overview of pipeline drugs for endometriosis in the US
  • Figure 3: Pipeline drugs for endometriosis, by company
  • Figure 4: Pipeline drugs for endometriosis, by drug type
  • Figure 5: Pipeline drugs for endometriosis, by classification
  • Figure 6: OBE2109 for Endometriosis (June 18, 2018): Phase Iib - EDELWEISS
  • Figure 7: Key upcoming events in endometriosis
  • Figure 8: Probability of success in the endometriosis pipeline
  • Figure 9: Licensing and asset acquisition deals in endometriosis, 2014-19
  • Figure 10: Parent patents in endometriosis
  • Figure 11: Clinical trials in endometriosis
  • Figure 12: Top 10 drugs for clinical trials in endometriosis
  • Figure 13: Top 10 companies for clinical trials in endometriosis
  • Figure 14: Trial locations in endometriosis
  • Figure 15: Endometriosis trials status
  • Figure 16: Endometriosis trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of endometriosis, 2017-26
  • Table 2: Marketed drugs for endometriosis
  • Table 3: Pipeline drugs for endometriosis in the US
  • Table 4: OBE2109 for Endometriosis (June 18, 2018)
  • Table 5: Proellex (Oral) for Endometriosis (July 17, 2017)
  • Table 6: Historical global sales, by drug ($m), 2013-17
  • Table 7: Forecasted global sales, by drug ($m), 2019-23
Back to Top